Evidence map›Paper›PMID 33026068›Full record

ArticleInflammatory bowel diseases2021

Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity.

Xin Fang, Yoshiki Vázquez-Baeza, Emmanuel Elijah, Fernando Vargas, Gail Ackermann, Gregory Humphrey, Rebecca Lau, Kelly C Weldon, Jon G Sanders, Morgan Panitchpakdi and 16 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 2 countries.

Xin FangDepartment of Bioengineering University of California, San Diego, CA, USA.
Yoshiki Vázquez-BaezaJacobs School of Engineering University of California, San Diego, CA, USA.
Emmanuel ElijahCenter for Microbiome Innovation University of California, San Diego, CA, USA.
Fernando VargasDepartment of Pharmacology University of California, San Diego, CA, USA.
Gail AckermannDepartment of Pediatrics University of California, San Diego, CA, USA.
Gregory HumphreyDepartment of Pediatrics University of California, San Diego, CA, USA.
Rebecca LauDepartment of Cellular and Molecular Medicine University of California, San Diego, CA, USA.
Kelly C WeldonCenter for Microbiome Innovation University of California, San Diego, CA, USA.
Jon G SandersDepartment of Bioengineering University of California, San Diego, CA, USA.
Morgan PanitchpakdiDepartment of Pharmacology University of California, San Diego, CA, USA.
Carolina CarpenterCenter for Microbiome Innovation University of California, San Diego, CA, USA.
Alan K JarmuschDepartment of Pharmacology University of California, San Diego, CA, USA.
Jennifer NeillDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Ara MirallesDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Parambir DulaiDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Matthew TsaiDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Austin D SwaffordCenter for Microbiome Innovation University of California, San Diego, CA, USA.
Larry SmarrDepartment of Computer Science and Engineering, University of California, San Diego, CA, USA.
David L BoyleDivision of Rheumatology, Department of Medicine, University of California, San Diego, CA, USA.
Bernhard O PalssonDepartment of Bioengineering University of California, San Diego, CA, USA.
John T ChangDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Pieter C DorresteinDepartment of Pharmacology University of California, San Diego, CA, USA.
William J SandbornDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
Rob KnightDepartment of Bioengineering University of California, San Diego, CA, USA.
Brigid S BolandDivision of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
University of California San Diego · USCornell University · USNovo Nordisk Foundation · DK

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tatiana Kisseleva · 2019 to 2026
$10.8M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
USING SINGLE-CELL RNA AND PROTEIN APPROACHES TO ELUCIDATE MOLECULAR DETERMINANTSAND PREDICTORS OF INFLAMMATORY BOWEL DISEASESK23DK123406 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOLAND, BRIGID S · 2020 to 2022
$720k
NCATS NIH HHS KL2 TR001444NCATS NIH HHS UL1 TR001442NIDDK NIH HHS K23 DK117058NIDDK NIH HHS K23 DK123406NIDDK NIH HHS P30 DK120515NIDDK NIH HHS T32 DK007202
6 · The paper itself

Abstract

backgroundMany studies have investigated the role of the microbiome in inflammatory bowel disease (IBD), but few have focused on surgery specifically or its consequences on the metabolome that may differ by surgery type and require longitudinal sampling. Our objective was to characterize and contrast microbiome and metabolome changes after different surgeries for IBD, including ileocolonic resection and colectomy.

methodsThe UC San Diego IBD Biobank was used to prospectively collect 332 stool samples from 129 subjects (50 ulcerative colitis; 79 Crohn's disease). Of these, 21 with Crohn's disease had ileocolonic resections, and 17 had colectomies. We used shotgun metagenomics and untargeted liquid chromatography followed by tandem mass spectrometry metabolomics to characterize the microbiomes and metabolomes of these patients up to 24 months after the initial sampling.

resultsThe species diversity and metabolite diversity both differed significantly among groups (species diversity: Mann-Whitney U test P value = 7.8e-17; metabolomics, P-value = 0.0043). Escherichia coli in particular expanded dramatically in relative abundance in subjects undergoing surgery. The species profile was better able to classify subjects according to surgery status than the metabolite profile (average precision 0.80 vs 0.68).

conclusionsIntestinal surgeries seem to reduce the diversity of the gut microbiome and metabolome in IBD patients, and these changes may persist. Surgery also further destabilizes the microbiome (but not the metabolome) over time, even relative to the previously established instability in the microbiome of IBD patients. These long-term effects and their consequences for health outcomes need to be studied in prospective longitudinal trials linked to microbiome-involved phenotypes.

Indexed as

Crohn DiseaseDigestive System Surgical ProceduresGastrointestinal MicrobiomeFecesHumansMetabolomeProspective Studiesgut microbiomeinflammatory bowel diseaseintestinal surgerymetabolomicsmetagenomics

Identifiers

PMID33026068
PMCPMC8047854
OpenAlexW3091927123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.